Following the warning letter it received last April, Perrigo announced that the Food and Drug Administration has arrived at the company's Allegan, Mich.-based facility for re-inspection.
A recent clinical trial involving a new drug formulation incorporating aspirin with soy-derived phosphatidylcholine found that the drug combination significantly can reduce irritation to the stomach and upper gastrointestinal tract.